UCB UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn'…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
IIdeal Investisseur | ||
IIdeal Investisseur | ||
AArtsenkrant | ||
![]() UCB (UCBJY) Upgraded to Buy: Here's Why UCB (UCBJY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | ||
LLe Temps | ||
LLa Liberté | ||
FFrapp | ||
BBelga Share | ||
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market. | ||
LLe Soir | ||
![]() Trump Strikes Medicaid Drug Price Deals With Nine Pharma Firms The Trump administration has struck new drug pricing agreements with nine biotech and pharmaceutical companies including UCB SA, Bridgebio Pharma Inc. and Sun Pharmaceutical Industries Ltd. | ||
UCB SA (UCBJF) (H1 2026) Earnings Call Highlights: Record Sales and Strategic Expansion Drive ... UCB SA (UCBJF) reports 23% net sales growth to EUR4.1 billion, with BIMZELX doubling to EUR1.5 billion and upgraded full-year guidance reflecting robust operating leverage. | ||
DDHnet | ||
DDHnet | ||

